SKYE_OUT_1 [2025-03-21 15:45:59 -0400] 1882 Bytes | 561 tokens | Cum: 561 tkns (7.01% of 8k)
==========================================================================

Alright, let’s light it up, because it's 3:45:58 PM on Fri Mar 21, 2025 -0400, and I'm charging into Skye Bioscience (SKYE), popping from 1.89 to 2.255. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

Here's the first list of news for Skye Bioscience:

C1 - Mar-20-25 09:59PM - Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period
C2 - Mar-20-25 09:59PM 09:58PM - Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript
C3 - Mar-20-25 09:59PM 04:01PM - Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
C4 - Mar-20-25 09:59PM 10:00AM - Here are the major earnings after the close today
C5 - Mar-19-25 05:35PM - Skye Bioscience Q4 2024 Earnings Preview
C6 - Mar-14-25 07:00AM - Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
C7 - Feb-27-25 06:00PM - Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C8 - Feb-24-25 07:00AM - Skye Bioscience to Participate in SXSW Session on Obesity

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Skye Bioscience (SKYE)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

SKYE_OUT_3 [2025-03-21 15:46:06 -0400] 1050 Bytes | 301 tokens | Cum: 864 tkns (10.80% of 8k)
==========================================================================

Showing C3 (chunk 1 of 6): C3:
**Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update**
Date: Mar-20-25 09:59PM 04:01PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/20/3046694/0/en/Skye-Bioscience-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html

March 20, 2025 16:01 ET| Source:Skye Bioscience, Inc.Skye Bioscience, Inc.

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and full year ended December 31, 2024, along with key accomplishments and upcoming milestones.

“Skye’s prime accomplishment in

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

SKYE_OUT_5 [2025-03-21 15:46:08 -0400] 1048 Bytes | 216 tokens | Cum: 1082 tkns (13.53% of 8k)
==========================================================================

Showing C3 (chunk 2 of 6): 2024 was the initiation and rapid advancement of its comprehensive Phase 2a clinical study of nimacimab, a novel and differentiated CB1 inhibitor,” said Punit Dhillon, President & CEO of Skye. “Maturation of the obesity therapeutics landscape, including expanding clinical evidence, M&A, and licensing, highlights the strategic importance of alternative mechanisms of action with attributes differentiated from incretins. We believe nimacimab’s product profile is well-positioned to potentially fulfill critical unmet needs in this rapidly evolving therapeutic area.

“Our team showed discipline in capital allocation and focus in executing the Company’s priorities. We surpassed our enrollment target ahead of schedule and have to-date executed the Phase 2a clinical plan on target and within our budget. We disclosed preclinical data in November 2024 which achieved significant dose-dependent weigh

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

SKYE_OUT_7 [2025-03-21 15:46:09 -0400] 1042 Bytes | 239 tokens | Cum: 1323 tkns (16.54% of 8k)
==========================================================================

Showing C3 (chunk 3 of 6): t loss, significant fat mass loss with lean mass preservation, and dose-dependent improvement in glucose tolerance. These outcomes are indicative of the potentially compelling attributes of Skye’s highly peripherally-restricted CB1 inhibitor. In 2025 and beyond we will continue to apply this discipline and focus. We are enthusiastic about our updated clinical development plan, which will dramatically speed up our path to important 52-week treatment data from this extension study. Robust data in 2025 and 2026 will be valuable to various stakeholders and inform our regulatory engagement for future studies and decision-making.”

Fourth Quarter and FullYear 2024 Financial Results:

Skye will host a conference call to discuss its FY 2024 and Q4 2024 results at 1:30 p.m. PT/4:30 p.m. ET today, March 20th. The live streaming of the call can be accessed at the SkyeInvestor Relationswebsite, alon

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

SKYE_OUT_9 [2025-03-21 15:46:10 -0400] 938 Bytes | 284 tokens | Cum: 1609 tkns (20.11% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-21T08:58:35Z - Citizens JMP Reiterates Market Outperform Rating on Skye Bioscience (SKYE)...
A2 - 2025-03-21T06:05:15Z - Skye Bioscience (NASDAQ:SKYE) Shares Down 31% - Time to Sell?...
A3 - 2025-03-21T01:58:54Z - Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript...
A4 - 2025-03-20T20:25:51Z - Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Up...
A5 - 2025-03-20T20:08:23Z - Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Up...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SKYE_OUT_11 [2025-03-21 15:46:13 -0400] 806 Bytes | 229 tokens | Cum: 1840 tkns (23.00% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
**Citizens JMP Reiterates Market Outperform Rating on Skye Bioscience (SKYE)**Date: 2025-03-21Source: {'uri': 'streetinsider.com', 'dataType': 'news', 'title': 'StreetInsider.com'}URL: https://www.streetinsider.com/Analyst+Comments/Citizens+JMP+Reiterates+Market+Outperform+Rating+on+Skye+Bioscience+%28SKYE%29/24530981.htmlCitizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $15.00 price target on Skye Bioscience (NASDAQ: SKYE).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

SKYE_OUT_13 [2025-03-21 15:46:15 -0400] 872 Bytes | 300 tokens | Cum: 2187 tkns (27.34% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-14T11:00:00Z - Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
B2 - 2025-02-27T23:00:00Z - Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
B3 - 2024-11-14T12:00:00Z - Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
B4 - 2024-10-10T18:18:28Z - Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
B5 - 2024-10-09T17:13:04Z - 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore
B6 - 2024-10-07T07:06:00Z - 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SKYE_OUT_15 [2025-03-21 15:46:18 -0400] 674 Bytes | 185 tokens | Cum: 2374 tkns (29.68% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/14/3042868/0/en/Skye-Bioscience-to-Announce-2024-Financial-Results-on-March-20th-2025.htmlSkye Bioscience, a clinical-stage biotechnology company, will host a conference call to discuss its 2024 fourth quarter and full-year financial results. The company is focused on developing next-generation molecules to treat obesity and other metabolic health disorders.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

SKYE_OUT_17 [2025-03-21 15:46:20 -0400] 1091 Bytes | 286 tokens | Cum: 2721 tkns (34.01% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-20 8-K Item 2.02 Results of Oper and Fin Cond.

On March 20, 2025, Skye Bioscience, Inc. (the Company or Skye) issued a press release reporting its financial results for the fourth quarter and full year ended December 31, 2024. The full text of the press release is att...

S2 - 2025-03-20 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Operation.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our CONS financial statements for the years ended ...

S3 - 2025-03-20 8-K Item 2.02 Results of Oper and Fin Cond.

On March 20, 2025, Skye Bioscience, Inc. (the Company or Skye) issued a press release reporting its financial results for the fourth quarter and full year ended December 31, 2024. The full text of the press release is att...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SKYE_OUT_19 [2025-03-21 15:46:25 -0400] 1038 Bytes | 211 tokens | Cum: 2934 tkns (36.68% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operation.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements for the years ended December 31, 2024 and 2023 together with notes thereto. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited, to those set forth under Risk Factors and elsewhere in this Annual Report.

Unless otherwise provided in this Annual Report, references to we, us, our and Skye in this discussion and analysis refer to Skye Bioscience, Inc., a Nevada corporation

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

SKYE_OUT_21 [2025-03-21 15:46:38 -0400] 5192 Bytes | 1527 tokens | Cum: 4572 tkns (57.15% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-----------------------+-------------------------+----------------------+----------------------+
| Volume: 528,196 | SMA50: -20.39% | Market Cap: 67.35M | Option/Short: Yes / Yes | Sales past 5Y: 0.00% | Sales Surprise: - |
+---------------------+-----------------------+-----------------------+-------------------------+----------------------+----------------------+
| Avg Volume: 174.89K | SMA200: -53.31% | Shs Outstand: 30.34M | Short Float: 12.33% | Employees: 11 | EPS Surprise: 13.79% |
+---------------------+-----------------------+-----------------------+-------------------------+----------------------+----------------------+
| Rel Volume: 3.26 | Perf Week: -11.20% | Shs Float: 17.57M | Short Ratio: 12.39 | Debt/Eq: 0.00 | P/E: - |
+---------------------+-----------------------+-----------------------+-------------------------+----------------------+----------------------+
| RSI (14): 41.12 | Perf Month: -29.07% | Inst Own: 43.95% | Short Interest: 2.17M | Sales Y/Y TTM: - | Earnings: Mar 20 AMC |
+---------------------+-----------------------+-----------------------+-------------------------+----------------------+----------------------+
| ATR (14): 0.30 | Perf Quarter: -31.69% | Insider Own: 42.09% | Beta: 1.82 | ROE: -54.82% | |
+---------------------+-----------------------+-----------------------+-------------------------+----------------------+----------------------+
| SMA20: -12.69% | Index: RUT | Insider Trans: -1.79% | Sales Q/Q: - | ROI: -27.98% | |
+---------------------+-----------------------+-----------------------+-------------------------+----------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Skye Bioscience, Inc. (SKYE) by Arora Puneet S. (Chief Medical Officer) on 2025-02-24
- Stock Option (Right to Buy): 38000 shares at $0 (D)

Inside Trans: Skye Bioscience, Inc. (SKYE) by Diep Tuan Tu (Chief Development Officer) on 2025-02-24
- Stock Option (Right to Buy): 150000 shares at $0 (D)

Inside Trans: Skye Bioscience, Inc. (SKYE) by Charych Deborah H. (Unknown Title) on 2025-02-24
- Stock Option (Right to Buy): 35000 shares at $0 (D)

Inside Trans: Skye Bioscience, Inc. (SKYE) by DHILLON PUNIT (Chief Executive Officer) on 2025-02-24
- Stock Option (Right to Buy): 250000 shares at $0 (D)

Inside Trans: Skye Bioscience, Inc. (SKYE) by Smith Karen L. (Unknown Title) on 2025-02-24
- Stock Option (Right to Buy): 35000 shares at $0 (D)

Inside Trans: Skye Bioscience, Inc. (SKYE) by Grayson Paul A. (Unknown Title) on 2025-02-24
- Stock Option (Right to Buy): 135000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: Skye Bioscience, Inc. Common Stock
Market Cap: 63710409.0
Shares Outstanding: 30338290
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -3898297.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.265
Average Volume: 175263.26
30-Day High: 3.18
30-Day Low: 1.89

[Detailed Financials: Q3 2024]
- Total Assets: $81,535,660.0
- Total Liabilities: $5,732,285.0
- Total Equity: $75,803,375.0
- Current Assets: $79,808,229.0
- Current Liabilities: $5,624,223.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.1

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-6,708,240.0

[Detailed Financials: Q2 2024]
- Total Assets: $87,261,531.0
- Total Liabilities: $14,452,480.0
- Total Equity: $72,809,051.0
- Current Assets: $87,004,463.0
- Current Liabilities: $14,322,573.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.2

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-9,222,053.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

SKYE_OUT_23 [2025-03-21 15:46:41 -0400] 676 Bytes | 167 tokens | Cum: 4986 tkns (62.32% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

SKYE_IN_25 [2025-03-21 15:46:41 -0400] 126 Bytes | 29 tokens | Cum: 5043 tkns (63.04% of 8k)
==========================================================================

====================================
[2025-03-21 12:46:41] # Analysis Completed
Elapsed Time: 43.92 seconds